Search - tctmd.com

Displaying 1 - 20 of 21

Sort: Relevancy | Date

News Opinion CV Team Dispatch

September 2024 Dispatch for the CV Team

L.A. McKeown

September 01, 2024

News Opinion CV Team Dispatch

August 2024 Dispatch for the CV Team

L.A. McKeown

August 01, 2024

News Conference News SCAI 2024

Women, Black Patients Less Likely to Get Advanced PE Therapy, Analysis Shows

L.A. McKeown

May 06, 2024

News Daily News

Top Endovascular News of 2023

L.A. McKeown

December 28, 2023

News Opinion CV Team Dispatch

November 2023 News Roundup

L.A. McKeown

November 01, 2023

News Daily News

Medtronic’s Renal Denervation System Fails to Sway FDA Advisory Panel

L.A. McKeown

August 23, 2023

News Daily News

As Renal Denervation Heads to Advisory Review, FDA Sets Out Key Questions

L.A. McKeown

August 18, 2023

News Daily News

BP Reduction With Renal Denervation Still Evident a Decade On

Michael O'Riordan

January 31, 2023

News Opinion CV Team Dispatch

September 2022 News Roundup

L.A. McKeown

September 01, 2022

News Opinion CV Team Dispatch

January 2022 News Roundup

L.A. McKeown

January 01, 2022

News Opinion CV Team Dispatch

December 2021 News Roundup

L.A. McKeown

December 01, 2021

News Conference News TCT 2021

Renal Denervation May Help Cut BP Meds, Sham-Controlled Trial Hints

Todd Neale

November 04, 2021

News Opinion CV Team Dispatch

November 2021 News Roundup

L.A. McKeown

November 01, 2021

News Conference News ACC 2021

Renal Denervation Lowers BP vs Sham Procedure: RADIANCE-HTN TRIO

Michael O'Riordan

May 16, 2021

News Conference News TCT 2020

Treating Accessory Arteries May Be Important in Renal Denervation

Todd Neale

October 18, 2020

News Daily News

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Michael O'Riordan

September 24, 2020

News Conference News ACC 2019

Renal Denervation May Lower Treatment Burden, as Well as Blood Pressure: RADIANCE-HTN SOLO

Michael O'Riordan

April 01, 2019

News Daily News

FDA Charts Path for ‘Resurrection’ of Device-Based Antihypertensive Therapies

Michael O'Riordan

December 06, 2018

News Industry News

Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease

August 14, 2015

News Industry News

FDA strengthens warning on NSAID labels

July 10, 2015

Advertisement

September 2024 Dispatch for the CV Team

August 2024 Dispatch for the CV Team

Women, Black Patients Less Likely to Get Advanced PE Therapy, Analysis Shows

Top Endovascular News of 2023

November 2023 News Roundup

Medtronic’s Renal Denervation System Fails to Sway FDA Advisory Panel

As Renal Denervation Heads to Advisory Review, FDA Sets Out Key Questions

BP Reduction With Renal Denervation Still Evident a Decade On

September 2022 News Roundup

January 2022 News Roundup

December 2021 News Roundup

Renal Denervation May Help Cut BP Meds, Sham-Controlled Trial Hints

November 2021 News Roundup

Renal Denervation Lowers BP vs Sham Procedure: RADIANCE-HTN TRIO

Treating Accessory Arteries May Be Important in Renal Denervation

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Renal Denervation May Lower Treatment Burden, as Well as Blood Pressure: RADIANCE-HTN SOLO

FDA Charts Path for ‘Resurrection’ of Device-Based Antihypertensive Therapies

Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease

FDA strengthens warning on NSAID labels

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content